Samsung Biologics has acquired its first plant within the US, shopping for 100% of the shares of Human Genome Sciences Inc from GSK for $280 million. The deal will considerably strengthen its place within the pharmaceutical market and keep away from prolonged building.
South Korean big Samsung Biologics has introduced the acquisition of its first manufacturing web site in america. The corporate is shopping for 100% of the shares of Human Genome Sciences Inc, a plant situated in Rockville, Maryland, from British GSK (GlaxoSmithKline). This was reported by Reuters, writes UNN.
Particulars
The $280 million deal will enable Samsung Biologics to considerably strengthen its place on this planet's largest pharmaceutical market. At the moment, the power's capability is 60,000 liters of drug substance, however the brand new proprietor is already planning a large-scale modernization.
Samsung Biologics plans extra investments to broaden the power's capability and modernize applied sciences
– the corporate stated in a press launch.
Phrases and prospects
The deal is predicted to shut definitively on the finish of the primary quarter of 2026. This transfer is a response to the rising long-term demand for contract manufacturing of biologics within the US.
The acquisition of a ready-made plant will enable the Korean producer to keep away from the prolonged stage of constructing "from scratch" and shortly begin working with American prospects.
Google proclaims first AI glasses with Gemini in 2026 in collaboration with Samsung and Warby Parker08.12.25, 21:04 • 3105 views
Leave a Reply